Mergers & acquisitions
Otsuka Pharmaceutical, based in Tokyo, Japan, is acquiring Waltham, Massachusetts-based Visterra for $430 million in cash. The deal is expected to close in the third quarter of this year.
Idera Pharmaceuticals and BioCryst Pharmaceuticals originally planned on January 22, 2018 to merge the two companies. Now the two companies announced the deal has been terminated.
It’s been a big year so far for activity in the U.S. biopharma market—record IPOs and plenty of big acquisitions. But things may be heating up in Europe as well.
Despite market volatility, ongoing debates about drug pricing, and various scandals such as the Theranos debacle, everything Martin Shkreli touches, and Novartis paying President Trump’s attorney Michael Cohen $1.2 million for access to the president, it hasn’t slowed down biotech startups or investors.
Abingworth Bioventures closed out its latest investment fund aimed at supporting life science companies with $315 million. The latest fund, ABV VII, will be used to support investments in Europe and the United States.
It’s hard to believe 2018 is half over. There have been plenty of interesting and important stories in the biopharma space this year. Here’s a look at our top 10 stories so far, counting down from 10 to the number one story.
So far during the first six months of the year, more than $100 billion has been spent on a myriad of acquisitions across the pharma and biotech industries.
Shares of Juniper Pharmaceuticals have soared more than 31 percent in premarket trading after the company announced it will be acquired by drug delivery company Catalent, Inc. in a deal with a total equity value of approximately $139.6 million.
Both “rare cancers” and “sub-populations of cancers” present a challenge to companies conducting clinical trials—finding enough patients for those trials.
It’s been a pretty good year for mergers and acquisitions in the biopharma industry. But the landscape for IPOs has been excellent as well, particularly in Massachusetts, which has recorded 13 IPOs since the beginning of the year.
PRESS RELEASES